Studies have shown that active fund managers routinely underperform the S&P500 index*​

Akari Therapeutics, Plc (NASDAQ: AKTX)

AKTX Stock Predictions and Ratings

WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
101.90%

AKTX Stock Analysis

AKTX PE Ratio:

AKTX PEG Ratio: Not Available

AKTX Forward EPS Growth (12 month): 0.00%

AKTX PS Ratio:

AKTX PSG Ratio: Not Available

AKTX Forward Revenue Growth (12 month): 0.00%

AKTX Articles

No data was found